FREEDOMM: Real-world outcomes with cilta-cel for heavily pretreated RRMM

Results from FREEDOMM, a retrospective, real-world study evaluating outcomes with ciltacabtagene autoleucel (cilta-cel) for the treatment of relapsed/refractory multiple myeloma (RRMM) after ≥4 prior lines of therapy (LoT), were published in Advances in Therapy by Ailawadhi et al. Outcomes were stratified according to bridging therapy (BT) use and regimen type (BT, n = 182; no BT, n = 60).

Key data: At a median follow-up of 11 months, estimated treatment-free interval (TFI) rates at 6, 12, and 18 months were 94.0%, 89.0%, and 80.3%, respectively; corresponding overall survival (OS) rates were 97.3%, 93.4%, and 93.4%. Median TFI and OS were not reached. BT regimens were heterogeneous, commonly including proteasome inhibitors (PIs; 43.4%), monoclonal antibodies (mAbs; 31.4%), alkylators (18.2%), and immunomodulatory drugs (IMiDs; 16.9%). Compared with no BT, receipt of BT was associated with numerically lower risks of a TFI event (adjusted hazard ratio [aHR], 0.76; 95% confidence interval [CI], 0.32–1.80; p = 0.526) and death (aHR, 0.48; 95% CI, 0.13–1.70; p = 0.254), although differences were not significant.

Key learning: In the real-world setting, cilta-cel was associated with durable TFI and OS in heavily pretreated patients with RRMM. BT was commonly used prior to infusion, although differences in outcomes according to BT use did not reach statistical significance.